<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on 04/03/2026 at 8:18 pm by All in One SEO v4.6.1.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://www.compoundingineurope.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Compounding in Europe</title>
		<link><![CDATA[https://www.compoundingineurope.com]]></link>
		<description><![CDATA[Compounding in Europe]]></description>
		<lastBuildDate><![CDATA[Tue, 22 Apr 2025 10:42:21 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://www.compoundingineurope.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/compounded-hormones-for-female-patients-a-survey-assessment-of-clinical-practices-in-the-united-states/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/compounded-hormones-for-female-patients-a-survey-assessment-of-clinical-practices-in-the-united-states/]]></link>
			<title>Compounded Hormones for Female Patients: A Survey Assessment of Clinical Practices in the United States</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:42:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/476-evaluation-of-the-in-vitro-percutaneous-absorption-of-progesterone-testosterone-estriol-and-estradiol-topical-compounded-formulations/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/476-evaluation-of-the-in-vitro-percutaneous-absorption-of-progesterone-testosterone-estriol-and-estradiol-topical-compounded-formulations/]]></link>
			<title>476. Evaluation of the In Vitro Percutaneous Absorption of Progesterone, Testosterone, Estriol and Estradiol Topical Compounded Formulations</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:37:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/595-in-vitro-evaluation-of-skin-distribution-and-human-dermal-papilla-cells-proliferation-for-minoxidil-5-topical-lotion-hydrogel/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/595-in-vitro-evaluation-of-skin-distribution-and-human-dermal-papilla-cells-proliferation-for-minoxidil-5-topical-lotion-hydrogel/]]></link>
			<title>595. In Vitro Evaluation of Skin Distribution and Human Dermal Papilla Cells Proliferation for Minoxidil 5% Topical Lotion Hydrogel</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:35:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/1120-in-vitro-percutaneous-absorption-of-extemporaneously-compounded-estradiol-formulations/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/1120-in-vitro-percutaneous-absorption-of-extemporaneously-compounded-estradiol-formulations/]]></link>
			<title>1120. In Vitro Percutaneous Absorption of Extemporaneously Compounded Estradiol Formulations</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:33:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/666-in-vitro-and-in-vivo-evaluation-of-wound-healing-by-phenytoin-2-and-misoprostol-0-0024-topical-hydrogel/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/666-in-vitro-and-in-vivo-evaluation-of-wound-healing-by-phenytoin-2-and-misoprostol-0-0024-topical-hydrogel/]]></link>
			<title>666. In Vitro and In Vivo Evaluation of Wound Healing by Phenytoin 2% and Misoprostol 0.0024% Topical Hydrogel</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:32:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/2415/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/2415/]]></link>
			<title>Physicochemical Stability of Extemporaneously Prepared Oral Suspension of Fluconazole 50 mg/mL in SuspendIt™</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:30:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/pitch-ointment-applications-in-scar-and-wound-management/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/pitch-ointment-applications-in-scar-and-wound-management/]]></link>
			<title>Pitch Ointment: Applications in Scar and Wound Management</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:29:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/case-report-of-a-human-pappilomavirus-infection-treated-with-green-tea-extract-and-curcumin-vaginal-compounded-medications/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/case-report-of-a-human-pappilomavirus-infection-treated-with-green-tea-extract-and-curcumin-vaginal-compounded-medications/]]></link>
			<title>Case Report of a Human Pappilomavirus Infection Treated with Green Tea Extract and Curcumin Vaginal Compounded Medications</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:28:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/clinical-efficacy-of-a-topical-compounded-formulation-in-male-androgenetic-alopecia-minoxidil-10-finasteride-0-1-biotin-0-2-and-caffeine-citrate-0-05-hydroalcoholic-solution/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/clinical-efficacy-of-a-topical-compounded-formulation-in-male-androgenetic-alopecia-minoxidil-10-finasteride-0-1-biotin-0-2-and-caffeine-citrate-0-05-hydroalcoholic-solution/]]></link>
			<title>Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2% and Caffeine Citrate 0.05% Hydroalcoholic Solution</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:27:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/glycopyrrolate-sorbitol-lollipops-for-drooling-two-case-reports/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/glycopyrrolate-sorbitol-lollipops-for-drooling-two-case-reports/]]></link>
			<title>Glycopyrrolate Sorbitol Lollipops for Drooling: Two Case Reports</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:27:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/case-based-learning-management-of-complex-regional-pain-syndrome-with-a-transdermal-unlicensed-medication/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/case-based-learning-management-of-complex-regional-pain-syndrome-with-a-transdermal-unlicensed-medication/]]></link>
			<title>Case-based learning: management of complex regional pain syndrome with a transdermal unlicensed medication</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:26:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/unlicensed-transdermal-medications-in-feline-patients-three-case-reports/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/unlicensed-transdermal-medications-in-feline-patients-three-case-reports/]]></link>
			<title>Unlicensed Transdermal Medications in Feline Patients: Three Case Reports</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:24:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/the-role-of-pharmaceutical-compounding-in-promoting-medication-adherence/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/the-role-of-pharmaceutical-compounding-in-promoting-medication-adherence/]]></link>
			<title>The Role of Pharmaceutical Compounding in Promoting Medication Adherence</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:23:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/vulvovaginal-symptoms-in-a-postmenopausal-woman-a-case-study/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/vulvovaginal-symptoms-in-a-postmenopausal-woman-a-case-study/]]></link>
			<title>Vulvovaginal Symptoms in a Postmenopausal Woman: A Case Study</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:22:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/case-study-personalized-oral-low-dose-naltrexone-titration-for-pain-management/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/case-study-personalized-oral-low-dose-naltrexone-titration-for-pain-management/]]></link>
			<title>Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:21:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/analysis-of-the-physical-characteristics-of-an-anhydrous-vehicle-for-compounded-pediatric-oral-liquids/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/analysis-of-the-physical-characteristics-of-an-anhydrous-vehicle-for-compounded-pediatric-oral-liquids/]]></link>
			<title>Analysis of the Physical Characteristics of an Anhydrous Vehicle for Compounded Pediatric Oral Liquids</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:20:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/testosterone-therapy-for-late-onset-hypogonadism-a-clinical-biological-and-analytical-approach-using-compounded-testosterone-0-5-20-topical-gels/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/testosterone-therapy-for-late-onset-hypogonadism-a-clinical-biological-and-analytical-approach-using-compounded-testosterone-0-5-20-topical-gels/]]></link>
			<title>Testosterone Therapy for Late-Onset Hypogonadism: A Clinical, Biological, and Analytical Approach Using Compounded Testosterone 0.5–20% Topical Gels</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:18:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/integrated-in-vivo-and-in-vitro-evaluation-of-a-powder-to-hydrogel-film-forming-polymer-complex-base-with-tissue-protective-and-microbiome-supportive-properties/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/integrated-in-vivo-and-in-vitro-evaluation-of-a-powder-to-hydrogel-film-forming-polymer-complex-base-with-tissue-protective-and-microbiome-supportive-properties/]]></link>
			<title>Integrated In Vivo and In Vitro Evaluation of a Powder-to-Hydrogel, Film-Forming Polymer Complex Base with Tissue-Protective and Microbiome-Supportive Properties</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:17:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/combination-therapy-of-oral-ldn-and-topical-pentoxifylline-rifampin-clindamycin-for-hidradenitis-suppurativa/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/combination-therapy-of-oral-ldn-and-topical-pentoxifylline-rifampin-clindamycin-for-hidradenitis-suppurativa/]]></link>
			<title>Combination Therapy of Oral LDN and Topical Pentoxifylline, Rifampin, Clindamycin for Hidradenitis Suppurativa</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:16:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/in-vitro-percutaneous-absorption-of-permeation-enhancing-estrogen-formulations/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/in-vitro-percutaneous-absorption-of-permeation-enhancing-estrogen-formulations/]]></link>
			<title>In Vitro Percutaneous Absorption of Permeation-Enhancing Estrogen Formulations</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 10:15:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/pediatric-oral-extemporaneous-preparations-and-practices-international-pharmaceutical-federation-fip-global-study/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/pediatric-oral-extemporaneous-preparations-and-practices-international-pharmaceutical-federation-fip-global-study/]]></link>
			<title>Pediatric Oral Extemporaneous Preparations and Practices: International Pharmaceutical Federation (FIP) Global Study</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 09:18:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/physicochemical-and-microbiological-stability-of-ursodiol-oral-compounded-suspensions/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/physicochemical-and-microbiological-stability-of-ursodiol-oral-compounded-suspensions/]]></link>
			<title>Physicochemical and Microbiological Stability of Ursodiol Oral Compounded Suspensions</title>
			<pubDate><![CDATA[Tue, 22 Apr 2025 09:15:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/contact-2/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/contact-2/]]></link>
			<title>Contact</title>
			<pubDate><![CDATA[Tue, 09 Jan 2024 22:38:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/]]></link>
			<title>Maria Carvalho</title>
			<pubDate><![CDATA[Sun, 18 Jan 2026 14:20:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/gallery/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/gallery/]]></link>
			<title>Posters</title>
			<pubDate><![CDATA[Sun, 18 Jan 2026 15:25:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/research/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/research/]]></link>
			<title>Compounding in Europe</title>
			<pubDate><![CDATA[Thu, 11 Jan 2024 10:12:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/teaching/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/teaching/]]></link>
			<title>Lectures</title>
			<pubDate><![CDATA[Thu, 04 Jan 2024 23:45:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/publications-2/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/publications-2/]]></link>
			<title>Publications</title>
			<pubDate><![CDATA[Mon, 06 May 2024 16:26:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/an-overview-of-veterinary-compounding-permeation-enhancing-topical-medications/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/an-overview-of-veterinary-compounding-permeation-enhancing-topical-medications/]]></link>
			<title>An Overview of Veterinary Compounding: Permeation-Enhancing Topical Medications</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:28:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/2060/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/2060/]]></link>
			<title>Compounded Medication for Patients with Rare Diseases</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:28:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/apotheekbereiding-van-weesgeneesmiddelen-op-een-rij/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/apotheekbereiding-van-weesgeneesmiddelen-op-een-rij/]]></link>
			<title>Apotheekbereiding van Weesgeneesmiddelen op een rij</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:27:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/2373/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/2373/]]></link>
			<title>The Role of Transdermal Compounding in Opioid Safety</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:27:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/management-of-psoriasis-with-a-xematop-topical-compounded-formula-a-case-report/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/management-of-psoriasis-with-a-xematop-topical-compounded-formula-a-case-report/]]></link>
			<title>Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:27:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/physical-and-chemical-stability-of-budesonide-mucoadhesive-oral-suspensions-mucolox/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/physical-and-chemical-stability-of-budesonide-mucoadhesive-oral-suspensions-mucolox/]]></link>
			<title>Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:27:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/2061/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/2061/]]></link>
			<title>Evaluation of the In Vitro Human Skin Percutaneous Absorption of Progesterone in Versabase® Using the Franz Skin Finite Dose Model</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:27:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/case-report-diabetic-foot-ulcer-infection-treated-with-topical-compounded-medications/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/case-report-diabetic-foot-ulcer-infection-treated-with-topical-compounded-medications/]]></link>
			<title>Case Report: Diabetic Foot Ulcer Infection Treated With Topical Compounded Medications</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:27:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/pharmacy-students-survey-perceptions-and-expectations-of-pharmaceutical-compounding/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/pharmacy-students-survey-perceptions-and-expectations-of-pharmaceutical-compounding/]]></link>
			<title>Pharmacy Student’s Survey: Perceptions and Expectations of Pharmaceutical Compounding</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:27:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/pp-006-extemporaneously-compounded-oral-medicines-in-spanish-hospital-pharmacies/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/pp-006-extemporaneously-compounded-oral-medicines-in-spanish-hospital-pharmacies/]]></link>
			<title>PP-006. Extemporaneously Compounded Oral Medicines in Spanish Hospital Pharmacies</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:26:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/compounding-practices-in-a-portuguese-community-pharmacy/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/compounding-practices-in-a-portuguese-community-pharmacy/]]></link>
			<title>Compounding Practices in a Portuguese Community Pharmacy</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:26:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/bibliography/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/bibliography/]]></link>
			<title>Formulas</title>
			<pubDate><![CDATA[Sat, 30 Jan 2021 06:56:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/literature-review-the-dual-role-of-domperidone-in-gastroparesis-and-lactation/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/literature-review-the-dual-role-of-domperidone-in-gastroparesis-and-lactation/]]></link>
			<title>Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:26:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/the-role-of-compounding-in-closing-therapeutic-gaps-abstracts-from-fip-2013-when-not-to-compound-and-considerations-before-compounding/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/the-role-of-compounding-in-closing-therapeutic-gaps-abstracts-from-fip-2013-when-not-to-compound-and-considerations-before-compounding/]]></link>
			<title>The Role of Compounding in Closing Therapeutic Gaps &#8211; Abstracts from FIP 2013: When Not to Compound and Considerations Before Compounding</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:26:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/extemporaneously-compounded-oral-medicines-in-european-hospital-pharmacies/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/extemporaneously-compounded-oral-medicines-in-european-hospital-pharmacies/]]></link>
			<title>Extemporaneously Compounded Oral Medicines in European Hospital Pharmacies</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:26:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/why-do-we-need-hospital-pharmacy-preparation/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/why-do-we-need-hospital-pharmacy-preparation/]]></link>
			<title>Why Do We Need Hospital Pharmacy Preparation?</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:26:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/current-compounding-practices-in-europe/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/current-compounding-practices-in-europe/]]></link>
			<title>Current Compounding Practices in Europe</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:26:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/compounding-around-the-world/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/compounding-around-the-world/]]></link>
			<title>Compounding Around the World</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:25:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/pubs/medicamentos-manipulados-regresso-ao-futuro/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/pubs/medicamentos-manipulados-regresso-ao-futuro/]]></link>
			<title>Medicamentos Manipulados: Regresso ao Futuro</title>
			<pubDate><![CDATA[Mon, 01 Jan 2024 14:25:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.compoundingineurope.com/index.php/organizations/]]></guid>
			<link><![CDATA[https://www.compoundingineurope.com/index.php/organizations/]]></link>
			<title>Organizations</title>
			<pubDate><![CDATA[Fri, 07 Dec 2018 12:54:06 +0000]]></pubDate>
		</item>
				</channel>
</rss>
